INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers http://novacyt.com/wp-content/uploads/2018/12/NOVACYT_CP_Droits-de-vote_2018-Dec.pdf

Visit Page

Completion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market

Novacyt q16 order in China Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign’s q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular

Visit Page

Liquidity Agreement Monthly Update and Total Voting Rights

PParis, France and Camberley, UK – 3 December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised

Visit Page